• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卡波西肉瘤:重新评估

Kaposi's sarcoma: a reevaluation.

作者信息

Orfanos C E, Husak R, Wölfer U, Garbe C

机构信息

Department of Dermatology, University Medical Center Steglitz, Free University of Berlin, Germany.

出版信息

Recent Results Cancer Res. 1995;139:275-96.

PMID:7541146
Abstract

Kaposi's sarcoma (KS) is a multicentric neoplasia of microvascular origin arising during development of immunodeficiency in human immunodeficiency virus (HIV)-infected individuals. More than 130 patients with HIV-associated KS (98% male homosexuals; median age, 35 years) have been diagnosed at the Department of Dermatology, University Medical Center Steglitz, Berlin, during the years 1982-1992. Mucocutaneous and visceral involvement was a common finding in patients with HIV-associated KS, increasing from 39% at the first visit to 65% at the last observation. In 90% of the patients significant immunosuppression was found (75% had a CD4+ count < 200/mm3) at the time of first diagnosis. However, immunosuppression was not a prerequisite for the development of KS, since the tumor had been diagnosed before severe immunosuppression was present in about 10% of the patients. Significant prognostic predictors for the final outcome were: (a) the degree of immunosuppression, (b) the presence of mucosal and visceral manifestation, and (c) the past history of opportunistic infections. The median survival time was 28 months in KS patients with more than 300 CD4+ lymphocytes (n = 18), but only 14 months in immunosuppressed (less than 300 CD4+ lymphocytes) individuals with KS (n = 70). The median survival time in the entire group evaluated (n = 89 patients) was 17 months after first diagnosis. In 71 HIV-infected individuals who died at the Berlin Department during the last 8 years, disseminated KS was the major direct or indirect cause of death (49% of cases). Therapeutic benefit for KS patients was observed after long-term administration of recombinant interferon alpha (rIFN-alpha; 9-18 million IU s.c. every 2 days) alone or combined with antiretroviral drugs such as zidovudine over several months. Prolongation of survival was found after such treatment modalities in 30%-40% of treated patients. Bleomycin and vincristine and other systemically used cytostatics have also been applied with moderate results. The etiology of HIV-associated KS is still unknown and coinfection with herpes simplex virus (HSV), cytomegalovirus (CMV), or human papillomavirus (HPV) as well as certain growth-stimulating cytokines (transforming growth factors, TGF; tumor necrosis factor alpha, TNF-alpha; interleukin-6, IL-6; tat; vascular endothelial growth factors, VEGF; oncostatin M) produced by HIV-infected cells may be cofactors. Overall, KS was found to be a tumor with high malignant potential, and the median survival times were short.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

卡波西肉瘤(KS)是一种多中心起源于微血管的肿瘤,发生于人类免疫缺陷病毒(HIV)感染个体免疫缺陷发展过程中。1982年至1992年间,柏林施泰格利茨大学医学中心皮肤科诊断出130多名与HIV相关的KS患者(98%为男性同性恋者;中位年龄35岁)。皮肤黏膜和内脏受累在与HIV相关的KS患者中很常见,从首次就诊时的39%增加到最后一次观察时的65%。90%的患者在首次诊断时发现有明显的免疫抑制(75%的患者CD4 + 细胞计数<200/mm³)。然而,免疫抑制并非KS发生的先决条件,因为约10%的患者在出现严重免疫抑制之前就已诊断出肿瘤。最终结局的重要预后预测因素为:(a)免疫抑制程度,(b)黏膜和内脏表现的存在情况,(c)机会性感染病史。CD4 + 淋巴细胞超过300个的KS患者(n = 18)的中位生存时间为28个月,但免疫抑制(CD4 + 淋巴细胞少于300个)的KS患者(n = 70)的中位生存时间仅为14个月。整个评估组(n = 89例患者)首次诊断后的中位生存时间为17个月。在过去8年中于柏林科室死亡的71例HIV感染个体中,播散性KS是主要的直接或间接死亡原因(49%的病例)。单独长期给予重组干扰素α(rIFN-α;每2天皮下注射900 - 1800万国际单位)或与齐多夫定等抗逆转录病毒药物联合使用数月后,观察到对KS患者有治疗益处。经此类治疗方式后,30% - 40%的治疗患者生存时间延长。博来霉素、长春新碱和其他全身使用的细胞抑制剂也已应用,效果一般。与HIV相关的KS的病因仍不清楚,单纯疱疹病毒(HSV)、巨细胞病毒(CMV)或人乳头瘤病毒(HPV)的合并感染以及HIV感染细胞产生的某些生长刺激细胞因子(转化生长因子,TGF;肿瘤坏死因子α,TNF-α;白细胞介素-6,IL-6;反式激活因子;血管内皮生长因子,VEGF;制瘤素M)可能是辅助因素。总体而言,KS被发现是一种具有高恶性潜能的肿瘤,中位生存时间较短。(摘要截选至400字)

相似文献

1
Kaposi's sarcoma: a reevaluation.卡波西肉瘤:重新评估
Recent Results Cancer Res. 1995;139:275-96.
2
Phase I/II trials of alpha-interferon alone or in combination with zidovudine as maintenance therapy following induction chemotherapy in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma.α-干扰素单独或与齐多夫定联合作为诱导化疗后维持治疗用于治疗获得性免疫缺陷综合征相关卡波西肉瘤的I/II期试验。
Semin Oncol. 1991 Oct;18(5 Suppl 7):53-7.
3
[Disseminated mucocutaneous Kaposi sarcoma in AIDS. Clinical and therapeutic experiences in 13 patients].[艾滋病相关播散性皮肤黏膜卡波西肉瘤。13例患者的临床及治疗经验]
Hautarzt. 1987 May;38(5):286-94.
4
Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.接受齐多夫定治疗的晚期人类免疫缺陷病毒病患者患卡波西肉瘤的危险因素。齐多夫定流行病学研究组。
Arch Intern Med. 1994 Mar 14;154(5):566-72.
5
A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma.一项关于重组人干扰素α-2a或人淋巴母细胞干扰素α-n1与齐多夫定联合应用于艾滋病相关卡波西肉瘤患者的I期研究。
J Acquir Immune Defic Syndr (1988). 1991;4(1):1-10.
6
One hundred and five Kaposi sarcoma patients: a clinical study in Xinjiang, Northwest of China.105例卡波西肉瘤患者:中国西北新疆地区的一项临床研究。
J Eur Acad Dermatol Venereol. 2014 Nov;28(11):1545-52. doi: 10.1111/jdv.12349. Epub 2013 Dec 19.
7
Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.高效抗逆转录病毒治疗后获得性免疫缺陷综合征相关卡波西肉瘤的消退:临床结局的生物学关联
J Natl Cancer Inst Monogr. 2001(28):44-9. doi: 10.1093/oxfordjournals.jncimonographs.a024256.
8
Overview of the management of AIDS-related Kaposi's sarcoma.艾滋病相关卡波西肉瘤的管理概述
Ann Pharmacother. 1996 Oct;30(10):1150-63. doi: 10.1177/106002809603001015.
9
Kaposi's sarcoma. An Update.卡波西肉瘤。最新进展。
Dermatol Surg. 1996 Mar;22(3):274-87.
10
Combination chemotherapy and alpha-interferon in the treatment of Kaposi's sarcoma associated with acquired immune deficiency syndrome.联合化疗与α干扰素治疗获得性免疫缺陷综合征相关的卡波西肉瘤
CMAJ. 1988 Oct 1;139(7):635-9.

引用本文的文献

1
Metastatic Kaposi's Sarcoma with Perirectal Involvement Diagnosed with Endoscopic Ultrasound-Guided EchoBrush Cytology Sampling.经内镜超声引导下回声刷细胞学采样诊断的伴有直肠周围受累的转移性卡波西肉瘤
Case Rep Gastroenterol. 2011 May;5(2):416-21. doi: 10.1159/000330480. Epub 2011 Jul 22.
2
Kaposin-B enhances the PROX1 mRNA stability during lymphatic reprogramming of vascular endothelial cells by Kaposi's sarcoma herpes virus.卡波辛-B 通过卡波济氏肉瘤疱疹病毒增强血管内皮细胞淋巴管重编程过程中的 PROX1 mRNA 稳定性。
PLoS Pathog. 2010 Aug 12;6(8):e1001046. doi: 10.1371/journal.ppat.1001046.
3
Human herpesvirus-8 in Kaposi's sarcoma of the conjunctiva in a patient with AIDS.
艾滋病患者结膜卡波西肉瘤中的人疱疹病毒8型
Jpn J Ophthalmol. 2006 Jan-Feb;50(1):7-11. doi: 10.1007/s10384-005-0268-y.
4
Oral manifestations in HIV infection: fungal and bacterial infections, Kaposi's sarcoma.HIV感染的口腔表现:真菌和细菌感染、卡波西肉瘤。
Med Microbiol Immunol. 2003 Aug;192(3):165-9. doi: 10.1007/s00430-002-0175-5. Epub 2003 Mar 5.
5
The significance of oral health in HIV disease.口腔健康在HIV疾病中的意义。
Sex Transm Infect. 2000 Aug;76(4):236-43. doi: 10.1136/sti.76.4.236.
6
Diagnosing HIV-related disease: using the CD4 count as a guide.诊断与HIV相关的疾病:以CD4细胞计数为指导
J Gen Intern Med. 1998 Feb;13(2):131-6. doi: 10.1046/j.1525-1497.1998.00031.x.